KHKeita Harada

Keita Harada

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Keita Harada has a total of 105 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Curcumin Suppresses Growth of Recurrent Colorectal Adenoma After Endoscopic Resection: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial

    by Tetsuji Takayama, Koichi Okamoto, Hideki Ishikawa, Kaizo Kagemoto, Tatsuhisa Yasaka, Takashi Hisabe, Koichi Kawabe, Toyotaka Kasai, Masaya Kubota, Masahito Shimizu, et al.

    INTRODUCTION: Experimental and limited clinical studies suggest that curcumin has chemopreventive activity in the colorectum. This large-scale clinical trial evaluated the efficacy and safety of curcumin in patients with previously endoscopically resected colorectal neoplasia. METHODS: This randomized, double-blind, placebo-controlled multicenter trial enrolled patients with previously resected colorectal neoplasia. Eligible patients were randomly assigned (1:1), using a stratified, computer-generated scheme to receive oral submicron-powdered curcumin (Theracurmin; 180 mg twice daily) or identical placebo capsules for 2 years. All analyses were performed according to a modified intention-to-treat principle including all randomly assigned patients who underwent the 2-year colonoscopy. RESULTS: Between April 1, 2016, and March 31, 2020, 577 patients were randomly assigned to curcumin (n = 287) or placebo groups (n = 290). The detection rate of recurrent colorectal adenomas at 2 years, the primary end point, did not differ significantly between groups (risk ratio 0.98; 95% confident interval 0.82–1.16). However, the detection rate of adenomas ≥6 mm, a prespecified lesion category recommended for endoscopic resection in Japanese guidelines, was significantly lower with curcumin (risk ratio, 0.56; 95% confident interval, 0.33–0.95; P = 0.04). The per-patient number of adenomas ≥6 mm was also significantly lower ( P = 0.03), and the median size of all detected adenomas was significantly smaller in the curcumin group ( P = 0.003). The inhibitory effect seemed more pronounced in patients with higher baseline adenoma burden and in men in exploratory analyses. Treatment-related adverse events were infrequent and mild. DISCUSSION: Curcumin inhibited the growth of recurrent colorectal adenomas, despite no significant reduction in the overall incidence of recurrence. This is the first large-scale randomized clinical trial demonstrating the suppressive efficacy of curcumin against colorectal neoplasia, and also highlighting the importance of incorporating growth-related endpoints, in addition to incidence-based or detection-based end points, in chemoprevention studies (jRCTs061180079).


  • Outcomes of noncurative endoscopic submucosal dissection for T1 colorectal cancer: Prospective, multicenter, cohort study in Japan

    by Shigetsugu Tsuji, Hisashi Doyama, Nozomu Kobayashi, Ken Ohata, Yoji Takeuchi, Akiko Chino, Hiroyuki Takamaru, Yosuke Tsuji, Kinichi Hotta, Keita Harada, et al.

    Objectives: This study investigated the incidence of lymph node metastasis and long‐term outcomes in patients with T1 colorectal cancer where endoscopic submucosal dissection (ESD) resulted in noncurative treatment. It is focused on those with deep submucosal invasion, a factor considered a weak predictor of lymph node metastasis in the absence of other risk factors.Methods: This nationwide, multicenter, prospective study conducted a post‐hoc analysis of 141 patients with T1 colorectal cancer ≥20 mm where ESD of the lesion resulted in noncurative outcomes, characterized by poor differentiation, deep submucosal invasion (≥1000 μm), lymphovascular invasion, high‐grade tumor budding, or positive vertical margins. Clinicopathologic features and patient prognoses focusing on lesion sites and additional surgery requirements were evaluated. Lymph node metastasis incidence in the low‐risk T1 group, identified by deep submucosal invasion as the sole high‐risk histological feature, was assessed.Results: Lymph node metastasis occurred in 14% of patients undergoing additional surgery post‐noncurative endoscopic submucosal dissection for T1 colorectal cancer. In the low‐risk T1 group, in the absence of other risk factors, the frequency was 9.7%. The lymph node metastasis rates in patients with T1 colon and rectal cancers did not differ significantly (14% vs. 16%). Distant recurrence was observed in one patient (2.3%) in the ESD only group and in one (1.0%) in the additional surgery group, both of whom had had rectal cancer removed.Conclusion: The risk of lymph node metastasis or distant occurrence was not negligible, even in the low‐risk T1 group. The findings suggest the need for considering additional surgery, particularly for rectal lesions (Clinical Trial Registration: UMIN000010136).


  • Open Access

    Short‐term and long‐term outcomes of submucosal dissection for residual or recurrent colorectal tumors after endoscopic resection: Analysis of a multicenter prospective study

    by Hirohito Tanaka, Toshio Uraoka, Nozomu Kobayashi, Ken Ohata, Yoji Takeuchi, Akiko Chino, Masayoshi Yamada, Yosuke Tsuji, Kinichi Hotta, Keita Harada, et al.

    Objectives: We previously demonstrated that a favorable long‐term prognosis indicated that endoscopic submucosal dissection (ESD) could be the standard treatment for large colorectal epithelial neoplasms, but the usefulness of ESD for local residual or recurrent tumors with submucosal fibrosis has not been fully demonstrated. The aim of the present study was to assess the usefulness of ESD for local residual or recurrent colorectal tumors.Methods: We conducted a nationwide multicenter prospective study to evaluate the outcomes of ESD for colorectal tumors. In this post hoc analysis, a total of 54 local residual or recurrent colorectal tumors in 54 patients were included, and we analyzed the short‐term and long‐term outcomes of ESD for these lesions.Results: The median size of the lesions was 16.0 (interquartile range [IQR] 11–25) mm. ESD was completed in 53 cases (98.1%) with a median procedure time of 65.0 min, but it was discontinued in one case because of submucosal cancer invasion. En bloc resection was achieved in 52 cases (96.3%), whereas R0 resection was achieved in 45 cases (83.3%). Intraoperative perforation was observed in four cases (7.4%) and delayed perforation in one (1.9%), but all cases could be managed conservatively. Delayed bleeding was not observed. There were no significant differences in short‐term outcomes between the rectal and colonic lesions. There was no recurrence of the tumor during the median follow‐up period of 60 (IQR 50–64) months.Conclusion: An analysis of our multicenter prospective study suggests that ESD is an effective salvage management for local residual or recurrent colorectal lesions.


  • Low Patient Weight and Long Intubation Time Are Key Factors for Pain during Colonoscopy

    by Shohei Oka, Keita Harada, Shumpei Yamamoto, Eriko Yasutomi, Shoko Igawa, Masayasu Ohmori, Mami Hirai, Yasushi Yamasaki, Toshihiro Inokuchi, Hideaki Kinugasa, et al.

    Although the clinical usefulness of colonoscopy has been established, the procedure remains painful for many patients. This study was designed to clarify the factors predicting colonoscopy-related pain. We evaluated 283 consecutive patients who completed a first-ever, total colonoscopy without sedatives or analgesics. The severity of pain symptoms was evaluated by a numeric rating scale (NRS) in a questionnaire immediately after the colonoscopy. Patient backgrounds and endoscopic findings were analyzed to evaluate their association with pain. Out of 283 patients, 53 scored their pain 0-1 on the NRS while 48 scored it 6-10. We defined the colonoscopies of the former and latter patients as painless and painful, respectively, and compared the two. Multivariate analyses revealed that low body weight (OR 4.95, 95%CI 1.89-12.99) and longer intubation time (OR 3.63, 95%CI 1.46-9.03) were significant risk factors for painful colonoscopy. To identify factors contributing to the increased intubation time, we divided subjects into short- and long-intubation-time groups based on a median insertion time of 7 min. Older age (OR 2.28, 95%CI 1.31-3.98), previous abdominal surgery (OR 1.93, 95%CI 1.13-3.32) and findings of invasive cancer (OR 10.90, 95%CI 1.34-88.90) were significant factors for longer intubation time.


  • Clinical utility of a serum glycome analysis in patients with colorectal cancer

    by Daisuke Takei, Keita Harada, Kazuhiro Nouso, Koji Miyahara, Chihiro Dohi, Hiroshi Matsushita, Hideaki Kinugasa, Sakiko Hiraoka, Shin‐Ichiro Nishimura, Hiroyuki Okada

    Background and Aim: Serum glycans are known to be good markers for the early diagnosis and prognostic prediction in many cancers. The aims of this study were to reveal the serum glycan changes comprehensively during the process of carcinogenesis from colorectal adenoma (CRA) to colorectal cancer (CRC) and to evaluate the usefulness of the glycan profiles as clinical markers for CRC.Methods: Serum samples were obtained from 80 histologically proven CRC and 36 CRA cases. The levels of glycans in the serum were examined with a comprehensive, quantitative, high‐throughput unique glycome analysis, and their diagnostic and prognostic abilities were evaluated.Results: Among 34 stably detected glycans, nine were differentially expressed between CRC and CRA. Serum levels of hybrid type glycans were increased in patients with CRC compared with those with CRA (P < 0.001), and both hybrid‐type and multi‐antennary glycans were significantly increased in advanced cancer cases. The glycan, m/z 1914, showed the highest diagnostic value among the decreased glycans, whereas m/z 1708 showed the highest among the increased glycans. The glycan ratio m/z 1708/1914 showed a higher area under the receiver operating characteristic curve (0.889) than any other single glycan or conventional tumor marker, such as carcinoembryonic antigen (0.766, P = 0.040) and carbohydrate antigen 19‐9 (0.615, P < 0.001). High m/z 1708/1914 was also correlated with an advanced cancer stage and short overall survival.Conclusion: Serum glycans, especially the m/z 1708/1914 ratio, were useful for the diagnosis, staging, and prognosis prediction of CRC.


  • Top Cited Papers

    Outcomes of endoscopic submucosal dissection for colorectal neoplasms: Prospective, multicenter, cohort trial

    by Nozomu Kobayashi, Yoji Takeuchi, Ken Ohata, Masahiro Igarashi, Masayoshi Yamada, Shinya Kodashima, Kinichi Hotta, Keita Harada, Hiroaki Ikematsu, Toshio Uraoka, et al.

    Objectives: Endoscopic mucosal resection (EMR) is the gold standard for the treatment of noninvasive large colorectal lesions, despite challenges associated with nonlifting lesions and a high rate of local recurrence. Endoscopic submucosal dissection (ESD) offers the possibility of overcoming these EMR limitations. However, a higher risk of complications and longer procedure time prevented its dissemination. As ESD now provides more stable results because of standardized techniques compared with those used earlier, this study aimed to quantify the rates of en bloc and curative resections, as well as ESD complications, in the present situation.Methods: A multicenter, large‐scale, prospective cohort trial of ESD was conducted at 20 institutions in Japan. Consecutive patients scheduled for ESD were enrolled from February 2013 to January 2015.Results: ESD was performed for 1883 patients (1965 lesions). The mean procedure time was 80.6 min; en bloc and curative resections were achieved in 1759 (97.0%) and 1640 (90.4%) lesions, respectively, in epithelial lesions ≥20 mm. Intra‐ and postprocedural perforations occurred in 51 (2.6%) and 12 (0.6%) lesions, respectively, and emergency surgery for adverse events was performed in nine patients (0.5%).Conclusions: This trial conducted after the standardization of the ESD technique throughout Japan revealed a higher curability, shorter procedure time, and lower risk of complications than those reported previously. Considering that the target lesions of ESD are more advanced than those of EMR, ESD can be a first‐line treatment for large colorectal lesions with acceptable risk and procedure time. (Clinical Trial Registration: UMIN000010136).


  • Open Access

    Virtual scale function of gastrointestinal endoscopy for accurate polyp size estimation in real-time: a preliminary study

    by Masato Yoshioka, Yuichi Sakaguchi, Daisuke Utsunomiya, Shinichiro Sonoda, Takeichi Tatsuta, Satoshi Ozawa, Yuichi Teramura, Keita Harada, Hideaki Kinugasa, Hiroyuki Okada

    Polyp size is an important risk factor for colorectal cancer. Many guidelines or reports of colonoscopy make recommendations or provide decision trees according to the size of the detected polyp/adenoma. For example, the recommendation of the colonoscopy surveillance interval after polypectomy is divided based on whether the adenoma size is ≥10  mm or less in some guidelines.1 – 3 According to the preservation and incorporation of valuable endoscopic innovations in real-time endoscopic assessments of the histology of diminutive colorectal polyps proposed by the American Society of Gastrointestinal Endoscopy,4 diminutive lesions smaller than 5 mm should be targeted for resection and discarded because they are associated with low rates of invasive cancer and advanced histology such as villous adenomas and highly atypical adenomas. Regarding the treatment policy for colorectal lesions, polyps of sizes ≤20  mm are assessed to determine whether they can be resected at once with a snare, and the treatment method is selected (either endoscopic mucosal resection or endoscopic submucosal dissection).5


  • Open Access

    A novel clip closure method using precutting and a reopenable clip after colorectal endoscopic submucosal dissection

    by Masayasu Ohmori, Yasushi Yamasaki, Shumpei Yamamoto, Hideaki Kinugasa, Keita Harada, Sakiko Hiraoka, Hiroyuki Okada

    Clip closure of mucosal defects after endoscopic resection has been shown to reduce delayed adverse events [1] [2]; however, closing large defects using a conventional clip can be difficult [1]. Thus, alternative clip closure techniques have been developed, but they still need improvement in terms of simplicity and solderability [3] [4]. We therefore modified an existing precutting technique [4] using a reopenable clip to close large mucosal defects. After resection of the lesion, multiple small incisions were performed circumferentially just outside the defect using a DualKnife J (Olympus, Tokyo). A reopenable clip (SureClip, Microtech, Nanjing) was opened, and one side of the claw was inserted into the incision on the anal side, while the other side of the claw was placed just inside the margin of the defect, and the claws were closed while catching the normal mucosa. Bringing the caught mucosa closer to the oral side of the defect, the clip was reopened to insert the opposite side of the claw into the oral-side incision. Finally, the claws were completely closed, and the normal mucosae of both sides were drawn together. The combination of mucosal incision and mucosal catching using a reopenable clip was easily achieved without clip slipping. After repeating the same procedures to minimize the defects, regular clips were added to close the defect completely. This method was applied in three patients with defect sizes between 33 and 71 mm located in the ascending colon, transverse colon, and rectum. The median (range) procedure time was 20 (10–26) minutes. Complete closure was easily achieved in all cases, and there were no adverse events during the perioperative period. A representative case is shown in [Fig. 1] and [Video 1]. Video 1 A novel clip closure method using mucosal precutting and reopenable clips to close large mucosal defects after endoscopic submucosal dissection for colonic lesions. Complete closure was easily achieved using this novel method. In conclusion, using a reopenable clip with multiple precut small circumferential mucosal incisions is an excellent method to facilitate the complete closure of large mucosal defects. Endoscopy_UCTN_Code_TTT_1AQ_2AJ Publication Date: 27 August 2021 (online) © 2021. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany


  • Open Access

    Switching between Three Types of Mesalazine Formulation and Sulfasalazine in Patients with Active Ulcerative Colitis Who Have Already Received High-Dose Treatment with These Agents

    by Eriko Yasutomi, Sakiko Hiraoka, Shumpei Yamamoto, Shohei Oka, Mami Hirai, Yasushi Yamasaki, Toshihiro Inokuchi, Hideaki Kinugasa, Masahiro Takahara, Keita Harada, et al.

    Background and aim: Oral mesalazine and sulfasalazine (SASP) are key drugs for treating ulcerative colitis (UC). The efficacy of switching from one of the several mesalazine formulations to another is largely unknown. This study assessed the efficacy of switching among three types of mesalazine formulation and SASP for UC therapy. Methods: UC patients receiving high-dose mesalazine/SASP who switched to other formulations due to disease activity were considered eligible. Efficacy was evaluated 2, 6, and 12 months after switching. Results: A total of 106 switches in 88 UC patients were analyzed. The efficacy at 2 months after switching was observed in 23/39 (59%) cases from any mesalazine formulation to SASP, in 18/55 (33%) cases from one mesalazine to another, and in 2/12 (17%) cases from SASP to any mesalazine formulation. Nine of 43 effective cases showed inefficacy or became intolerant post-switching. Delayed efficacy more than two months after switching was observed in four cases. Steroid-free remission was achieved in 42/106 (39%) cases—within 100 days in 35 of these cases (83%). Conclusions: Switching from mesalazine to SASP was effective in more than half of cases. The efficacy of switching between mesalazine formulations was lower but may be worth attempting in clinical practice from a safety perspective.


  • Open Access

    Acute Appendicitis Caused by Previous Endoscopic Submucosal Dissection for an Adenoma Adjacent to the Appendiceal Orifice

    by Ryo Kato, Keita Harada, Kei Harada, Daisuke Takei, Yuusaku Sugihara, Shiho Takashima, Toshihiro Inokuchi, Masahiro Takahara, Sakiko Hiraoka, Yasushi Omura, et al.

    Endoscopic submucosal dissection (ESD) is a groundbreaking treatment for tumors adjacent to the appendiceal orifice that are difficult to remove by conventional endoscopic mucosal resection, and successful cases are increasingly reported. However, little is known about the subsequent complications, especially long-term complications. A female in her early 70s with a 15-mm cecal tumor adjacent to the appendiceal orifice – discovered incidentally during a screening colonoscopy – underwent hybrid ESD of the lesion. We completely resected the tumor, and she was discharged 5 days later with a pathological diagnosis of high-grade tubular adenoma. Ten months postoperatively, she experienced sudden-onset right lower quadrant pain and was diagnosed with acute appendicitis at another hospital. Due to suspicion that her condition was the result of residual tumor, her surgeon performed an emergency laparoscopic cecectomy. The pathological examination of the resected specimen showed thick scarring adjacent to the appendiceal orifice and no residual tumor. The previous ESD was identified as the cause of the scar, and the scar was the only finding to account for the patient’s appendicitis. This case is significant because the patient required additional surgery due to a complication of ESD. Further, it indicates that acute appendicitis may be a late complication of submucosal dissection near the appendiceal orifice. As ESD becomes more widely used, it is likely that more cecal tumors will be treated endoscopically. It is important to be aware of the late complications of ESD for these tumors.